The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment

Wilffert, Bob; Hadithy, A. F. Y. Al; Sing, V. J.; Matroos, Glenn E.; Hoek, Hans W.; Os, Jim van; Bruggeman, Richard; Brouwers, Jacobus; Harten, Peter N. van

doi:10.1177/0269881108091594

Cited by 42 publications

(27 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A meta-analysis found an association of the C allele in the 102T/C polymorphism of HTR2A with TD. 164 Nonetheless, there are numerous negative findings for this SNP as well (for example, see Wilffert et al 165 ). Studies also reported positive results with the -1438G/A 166 in HTR2A and the Cys23Ser polymorphism in HTR2C (for example, see Al Hadithy et al 156 ).…”

Section: Td and Epssmentioning

confidence: 99%

Pharmacogenetics of Antipsychotics

2014

View full text Add to dashboard Cite

Objective: During the past decades, increasing efforts have been invested in studies to unravel the influence of genetic factors on antipsychotic (AP) dosage, treatment response, and occurrence of adverse effects. These studies aimed to improve clinical care by predicting outcome of treatment with APs and thus allowing for individualized treatment strategies. We highlight most important findings obtained through both candidate gene and genome-wide association studies, including pharmacokinetic and pharmacodynamic factors. Methods:We reviewed studies on pharmacogenetics of AP response and adverse effects published on PubMed until early 2012. Owing to the high number of published studies, we focused our review on findings that have been replicated in independent studies or are supported by meta-analyses.Results: Most robust findings were reported for associations between polymorphisms of the cytochrome P450 system, the dopamine and the serotonin transmitter systems, and dosage, treatment response, and adverse effects, such as AP-induced weight gain or tardive dyskinesia. These associations were either detected for specific medications or for classes of APs. Conclusion:First promising and robust results show that pharmacogenetics bear promise for a widespread use in future clinical practice. This will likely be achieved by developing algorithms that will include many genetic variants. However, further investigation is warranted to replicate and validate previous findings, as well as to identify new genetic variants involved in AP response and for replication of existing findings. W W W La pharmacogénétique des antipsychotiquesObjectif : Au cours des dernières décennies, des efforts croissants ont été déployés dans des études visant à percer l'influence des facteurs génétiques sur le dosage des antipsychotiques (AP), la réponse au traitement, et la survenue d'effets indésirables. Ces études voulaient améliorer les soins cliniques en prédisant le résultat du traitement par AP, et en donnant lieu ainsi à des stratégies de traitement individualisées. Nous présentons les résultats les plus importants obtenus par des études tant de gènes candidats que d'association pangénomique, notamment les facteurs pharmacocinétiques et pharmacodynamiques. Méthodes :Nous avons passé en revue les études sur la pharmacogénétique de la réponse aux AP et des effets indésirables publiées dans PubMed jusqu'au début de 2012. Vu le nombre élevé d'études publiées, notre revue a mis l'accent sur les résultats qui ont été reproduits dans des études indépendantes ou qui sont soutenus par des méta-analyses.

show abstract

Section: Td and Epssmentioning

confidence: 99%

Pharmacogenetics of Antipsychotics

2014

View full text Add to dashboard Cite

show abstract

“…Of these, 18 assessed the association between TD and DRD3 Ser9Gly. Two were excluded because the TD outcome was only examined continuously using mean AIMS scores [Basile et al, 1999;Wilffert et al, 2008]. Two conference abstracts were also excluded [Utsunomiya et al, 2006;Zai et al, 2007a].…”

Section: Literature Collectionmentioning

confidence: 99%

The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: A meta‐analysis

Tsai

North

West

et al. 2009

American J of Med Genetics Pt B

View full text Add to dashboard Cite

To elucidate a widely suspected but inconclusive association between rs6280 in the dopamine receptor 3 gene (DRD3) and prevalence of tardive dyskinesia (TD), we conducted a meta-analysis of studies obtained in a systematic search of several bibliographic systems. We conducted several analyses of funnel plot asymmetry, overall heterogeneity, and study characteristics in analyses analogous to general, dominant and recessive inheritance models with the prevalence odds ratio (POR) as the measure of association. Thirteen eligible studies were identified with publication dates between 1997 and 2008. Evidence of funnel plot asymmetry was discerned in the dominant and general model analyses, but not in the recessive model analysis. Stratified analyses indicated that publication year, TD assessment method (Schooler-Kane criteria or other) and TD assessment frequency (single or repeated) were important study characteristics associated with heterogeneous PORs across studies. Studies conducted among patients with older age, fewer women or European (compared with Asian) ancestry reported stronger average PORs. Summary POR estimates under the dominant and general inheritance models were not warranted due to funnel plot asymmetry and heterogeneity. Under the recessive model, the summary estimate was POR = 0.93 (95% confidence interval: 0.70-1.23). We conclude that there is no or little association between DRD3 rs6280 polymorphisms and prevalence of TD.

show abstract

“…Cardiovascular ranked second with Puerto Rico [25][26][27][62][63][64] and Costa Rica [11,15,16,50,60,65,113] as the main contributors. Neurology/psychiatry placed third with a greater contribution of the Caribbean islands of Curaçao [85,86,110], Martinique [87], Jamaica [56,61], Cuba [82] and Puerto Rico [35,36,66,95] (Figure 3). These results are in agreement with the global trend of scientific research in these areas [10].…”

Section: Pharmacogenetic Research In Central America and The Caribbean mentioning

confidence: 99%

Pharmacogenetic Research Activity in Central America and the Caribbean: A Systematic Review

et al. 2016

View full text Add to dashboard Cite

Aim: The present review was aimed at analyzing the pharmacogenetic scientific activity in Central America and the Caribbean. Materials & methods: A literature search for pharmacogenetic studies in each country of the region was conducted on three databases using a list of the most relevant pharmacogenetic biomarkers including ‘phenotyping probe drugs’ for major drug metabolizing enzymes. The review included 132 papers involving 47 biomarkers and 35,079 subjects (11,129 healthy volunteers and 23,950 patients). Results: The country with the most intensive pharmacogenetic research was Costa Rica. The most studied medical therapeutic area was oncology, and the most investigated biomarkers were CYP2D6 and HLA-A/B. Conclusion: Research activity on pharmacogenetics in Central American and the Caribbean populations is limited or absent. Therefore, strategies to promote effective collaborations, and foster interregional initiatives and research efforts among countries from the region could help for the rational clinical implementation of pharmacogenetics and personalized medicine.

show abstract

The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment

Cited by 42 publications

References 43 publications

Pharmacogenetics of Antipsychotics

Pharmacogenetics of Antipsychotics

The DRD3 rs6280 polymorphism and prevalence of tardive dyskinesia: A meta‐analysis

Pharmacogenetic Research Activity in Central America and the Caribbean: A Systematic Review

Contact Info

Product

Resources

About